Sign In
Buy IFRX
$2.06
-0.110 (-5.07%)
At Close: Jun 03, 2026
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
09:51pm, Friday, 08'th May 2026
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
04:04pm, Friday, 08'th May 2026
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company c
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
08:15am, Friday, 08'th May 2026
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
08:30am, Wednesday, 06'th May 2026
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
08:25am, Wednesday, 06'th May 2026
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
07:30am, Monday, 04'th May 2026
JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced n
InflaRx to Report First Quarter 2026 Results on May 7, 2026
07:30am, Friday, 01'st May 2026
JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced t
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
07:30am, Tuesday, 28'th Apr 2026
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company�
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
07:30am, Thursday, 09'th Apr 2026
JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
07:30am, Tuesday, 31'st Mar 2026
JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announc
InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts
03:17am, Monday, 30'th Mar 2026
InflaRx N.V. (NASDAQ: IFRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat Ratings repor
Reviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)
01:31am, Friday, 27'th Mar 2026
InflaRx (NASDAQ: IFRX - Get Free Report) and Athira Pharma (NASDAQ: ATHA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
09:46am, Thursday, 19'th Mar 2026
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18.
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
07:30am, Thursday, 19'th Mar 2026
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readine
